The US Food and Drug Administration recently announced reapproval of gemtuzumab ozogamicin (GO) for treatment of CD33-positive acute myeloid leukemia (AML), thus opening up opportunities to develop ...

M2T-CD33 has received orphan drug designation for AML, offering incentives like tax credits and market exclusivity. The M2T platform is a novel immunotherapy approach targeting CD33-positive leukemic ...

Gemtuzumab ozogamicin (GO, Mylotarg) is a targeted therapeutic agent in which an anti-CD33 antibody is chemically coupled to a highly cytotoxic calicheamicin derivative through a hydrolysable linker.

Digital Fusion-Gene expression profiling in acute leukemia (AL): Clinical validation of throughput molecular technology in laboratory medicine. Long-term bosutinib (BOS) for Philadelphia ...

BOSTON, July 12, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced plans for a Phase I adoptive ...

Acute myeloid leukemia (AML) is one of the most common forms of cancer in children and adults. CD33, a protein often expressed on the surface of leukemic cells, has been a long-standing target for AML ...

Acute myeloid leukemia (AML) isn’t the most commonly known cancer. It is, however, one of the deadliest—an awful rare malignancy of the blood and bone marrow whose victims are already older and frail, ...

NEW YORK--(BUSINESS WIRE)--iCell Gene Therapeutics, LLC announced results from a study ongoing at Chengdu Military General Hospital of ICG144, the first CLL1-CD33 Compound CAR T-cell (cCAR) in ...

The positive preliminary SENTI-202 clinical data was presented on April 27 in a Clinical Trials Oral Minisymposium at the American Association for Cancer Research (AACR) Annual Meeting 2025 in an ...

The Food and Drug Administration (FDA) extended the indication of Mylotarg (gemtuzumab ozogamicin) to include the treatment of children aged one month or older with newly diagnosed CD33-positive acute ...